Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec induced endogenous factor VIII production and significantly reduced bleeding and ...
Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label phase II study No significant financial relationships to ...
BRISBANE, Calif. & NEW YORK--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE), today announced updated follow-up results from the ...
THE separation of Factor VIII activity from fibrinogen is of considerable importance. From the therapeutic point of view it would seem desirable when treating haemophiliacs to use a protein fraction ...
SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of lentiviral vector-transduced autologous hematopoietic stem cells (HSCs) increased ...
Setting: Two tertiary academic centers. Patients: We enrolled children younger than 18 years who were admitted to the PICU within 24 hours after insertion of a central venous catheter. We excluded ...
Active ingredient: Antihemophilic Factor (recombinant): nominally 250 IU, 500 IU, 1,000 IU, or 2,000 IU per vial; powder for IV infusion after reconstitution; plasma/ albumin-free; preservative-free; ...
PATIENTS with factor VIII deficiency and prolonged skin bleeding time (von Willebrand's syndrome) who receive fresh blood or plasma from normal donors or from patients with hæmophilia A with very low ...
Valoctocogene roxaparvovec conferred sustained bleeding control at 2 years among a cohort of men with severe hemophilia A, according to phase 3 study results published in The New England Journal of ...
NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data from the Phase ...
A single infusion of the gene therapy valoctocogene roxaparvovec led to significantly reduced bleeding rates that persisted in men with severe hemophilia A, 2-year results from the phase III GENEr8-1 ...
The latest trial results for its hemophilia A gene therapy suggest it may eliminate or significantly reduce the need for weekly infusions. Hemophilia A patients are at risk of spontaneous bleeds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback